Oral azacitidine prolongs survival of patients with AML in remission independent of measurable residual disease status

Added 132 days ago (08.01.2022)
Authors: Gail J Roboz; Farhad Ravandi; Andrew H Wei; Hervé Dombret; Felicitas Thol; Maria Teresa Voso; Andre C Schuh; Kimmo Porkka; Ignazia La Torre; Barry S Skikne; Jianhua Zhong; C L Beach; Alberto Risueño; Daniel Lopes de Menezes; Gert J Ossenkoppele; Hartmut Döhner
Journal: Blood
Read article